In order to address this knowledge void and due to the potential to achieve elevated levels of efficacy and wider margins-of-safety, griseofulvin was evaluated for anti-neoplastic cytotoxicity against chemotherapeutic-resistant mammary carcinoma (SKBr-3) both alone and simultaneously in dual combination with gemcitabine-(C4-amide)-[anti-HER2/neu]. The gene discussed is ERBB2; the disease is breast carcinoma.